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Abstract
The hepatitis C viral (HCV) infection is a global health burden, WHO estimates 130–150 
million people chronically infected with hepatitis C virus worldwide. Additional 3–4 
million people become newly infected annually and more than 350,000 people die each 
year of HCV-related liver diseases. HCV infection exhibits higher genetic diversity with 
regional variations in genotypic prevalence resulting big challenges on disease manage-
ment. Introduction of DAAs revolutionised the new era of all oral therapy in treatment 
of chronic hepatitis C infection and is the regimens of choice in present days. However, 
IFN-based combination therapy with sofosbuvir has promising efficacy in genotypes 3, 
4, 5 or 6 infections compared to genotypes 1 and 2 infections. So, these regimens could be 
an option in DAAs regimen failure cases. The poor availability of data on recent DAAs 
(IFN-free) regimens questioned on regular use and cost effectiveness is the another chal-
lenge with DAAs regimens. So phase III trials (sofosbuvir and velpatasvir) of recent 
DAAs with pangenotypic actions and better tolerability in HCV infected patients are the 
future advances in treatment of chronic hepatitis C. After all those recent combination 
therapies with better SVR, the combination of pegylated interferon with ribavirin is the 
only option available where unavailability of other regimens still exists.
Keywords: hepatitis C virus, HCV genotypes, pegylated interferon, direct-acting 
antivirals, sustained virological response
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1. Introduction
Hepatitis C virus (HCV) is a global public health problem causing progressive liver disease. 
The World Health Organization (WHO) estimates 130–150 million people chronically 
infected worldwide, which corresponds to 2–2.5% of world’s total population. Additional 
3–4 million people becoming newly infected annually and more than 350,000 people die 
each year due to HCV-related diseases. Primary HCV infection causes acute hepatitis 
(AHC), asymptomatic in majorities; however, it can progress to chronicity in about 55–85% 
cases and spontaneous remission within 6 months without treatment in 15–45% [1–3]. 
Chronic hepatitis C (CHC) frequently presents with complications such as liver cirrhosis, 
liver failure, and hepatocellular carcinoma (HCC). In CHC, 15–30% have risk of cirrho-
sis of liver within 20 years and risk of HCC in cirrhotic is approximately 2–4% per year. 
Decompensated cirrhosis leads to death in 50–70% of cases without liver transplantation 
after 5 years. Difficulties occur in determining number of new HCV infections, as most of 
the acute cases are not detected clinically. Less than 25% of acute cases of hepatitis C are 
only clinically apparent [1, 4–6].
Hepatitis C virus (HCV) is an envelope, single-stranded RNA virus of genus hepacivirus 
within the Flaviviridae family. HCV has seven genotypes (GT 1–7) with 67 subtypes and 
20 provisional subtypes [7]. Each genotype of HCV has its own geographical variation. 
GT-1 is the most prevalent worldwide, one third in East Asia followed by GT-3; GT-2, 4, 
and 6; and GT-5 is the least prevalent [8]. The prevalence of HCV GT-1 and 3 dominate in 
most of the countries irrespective of economic status while HCV GT-4 and 5 are prevalent 
largely in countries with lower income [7, 8]. HCV subtypes 1a and 1b are the most com-
mon genotypes in the United States and also in Europe while subtype 1b is predominant 
in Japan [9]. HCV subtypes 2a and 2b are relatively common in North America, Europe, 
and Japan, subtype 2c is common in Northern Italy. Although, GT-3 has endemic strain 
in South Asia, 3a is especially prevalent in intravenous drug abusers in Europe and in the 
United States. GT-4 is prevalent in North Africa and Middle East; GT-5 seems to be con-
fined to South Africa and GT-6 in Southeast Asia. A newly identified GT-7 isolated from a 
Central African (Congolese) immigrant in Canada [9]. The increased risk of HCV is highest 
among persons who inject drugs (PWID), global prevalence of HCV among PWID is 67%; 
HIV infected person, men who have sex with men (MSM); unsafe medical procedures-
recipients of infected blood products or invasive procedures in health care facilities with 
inadequate infection control practice. Vertical or perinatal transmission of HCV occurs in 
up to 4–8% of cases, and transmission risk among mothers of HIV infection is estimated 
17–25% [9–11].
The HCV infection is the public health problem and global burden, and the early diagnosis 
and treatment are necessary. The treatment of HCV infection was begun with the approval of 
interferon (IFN) by the Food and Drug Administration (FDA) in 1991, followed by combined 
IFN with ribavirin (RBV) in 1998 and then directly acting antiviral agents (Table 1). Until 
approval of directly acting antiviral agents, combination of pegylated interferon alfa (PegIFN 
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alfa) and ribavirin (RBV) was the standard treatment for all genotypic infections (Figure 1) 
[4, 12]. Over the past few years, the treatment options of HCV have exponentially grown. 
The development of directly acting antiviral (DAA) therapy, targeting non-structural proteins 
involved in replication of HCV revolutionised in the treatment of HCV infection. The com-
bination of DAAs with or without PegIFN alfa regimens is assessed in different studies, and 
Year Generic Genotypes (SVR)
1991 Interferon-alfa-2b
1996 Interferon-alfa-2a
1997 Consensus interferon
All standard interferon SVR rates (approximately) Genotype 1 (9%)
Genotypes 2, 3 (30%)
1998 Interferon-alfa plus ribavirin Genotype 1 (29%)
Genotypes 2, 3 (62%)
2001 PegInterferon-alfa-2b Genotype 1 (14%)
Genotypes 2, 3 (47%)
2001 PegInterferon-alfa-2b/ribavirin Genotype 1 (47%)
Genotypes 2–6 (75%)
2002 PegInterferon-alfa-2a Genotype 1 (28%)
Genotypes 2, 3 (56%)
2003 Pegylated alfa-2a/ribavirin Genotype 1 (51%)
Genotypes 2–6 (70%)
Genotypes 2, 3 (82%)
2011 Boceprevir/PEG/RBV Genotype 1 (66%)
2011 Telaprevir/PEG/RBV Genotype 1 (79%)
2013 Simeprevir/PEG/RBV Genotype 1 (up to 80%)
2013 Sofosbuvir/PEG/RBV Genotype 1 (up to 92%)
Genotype 4 (92%)
2013 Sofosbuvir/RBV Genotype 2 (up to 100%)
Genotype 3 (up to 92%)
2014 Sofosbuvir/simeprevir/RBV Genotype 1 (up to 92%)
2014 Sofosbuvir/ledipasvir Genotypes 1, 4, 5, 6 (up to 100%)
2014 Ombitasvir/paritaprevir/ritonavir/dasabuvir with/without RBV Genotype 1 (up to 100)
2015 Daclatasvir for use with sofosbuvir Genotype 3 (up to 98%)
2015 Ombitasvir, paritaprevir and ritonavir plus RBV Genotype 4 (up to 100%)
PEG, pegylated interferon by injection; RBV, ribavirin (pills), HCV inhibitors are pills; SVR, sustained virological 
response, SVR 12, 24-viral cure.
Reference: http://hcvadvocate.org/treatment/drug-pipeline/#Quick
Table 1. FDA approved medications for treatment of Hepatitis C infections.
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their efficacies in treatment of different HCV genotypes are evaluated individually. Recently, 
the combination of IFN-free DAAs regimens with or without ribavirin is evaluated as “All 
oral regimens” for treatment of HCV infection in different genotypes with better efficacy and 
tolerability [13]. The current treatment strategies for HCV are based on HCV genotyping; 
and HCV RNA load determination before, during, and after antiviral therapy; then selection 
of agents that are active against the isolated specific HCV genotype [4, 12, 14]. The aim of 
this review is to compare the efficacy of IFN-based and IFN-free regimens (DAAs combina-
tion therapy) on the basis of sustained virological response (SVR) rates in HCV genotypic 
infections.
2. Treatment
The primary goal of HCV treatment is to cure the infection. The obtaining sustained virologi-
cal response (SVR) is defined as undetectable HCV RNA in 12 weeks (SVR 12) or 24 weeks 
(SVR 24) after treatment completion. Cure rate, which achieves SVR, is more than 99%. SVR is 
generally associated with resolution of liver disease in patient without cirrhosis, but the patient 
with cirrhosis remains risk of life-threatening complications. However, the hepatic fibrosis 
may regress, and risk of complications like hepatic failure and portal hypertension is reduced. 
The risk of HCC and all causes of mortality are significantly reduced, nevertheless, not elimi-
nated in cirrhotic patients who clear HCV compared to untreated patients and non-sustained 
Figure 1. Combination of PegIFN-alfa and ribavirin for the treatment of HCV infections according to genotypes [4]. 
HCV, hepatitis C virus; RNA, ribonucleic acid; RVR, rapid virological response; DAAs, directly acting antivirals; cEVR, 
complete early virological response.
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virological responders [4, 15–17]. The endpoint of therapy is an SVR after therapy as assessed 
by sensitive molecular method with the lower limit of HCV RNA detection ≤15 International 
Units/ml (IU/ml) [4, 12, 14].
2.1. Efficacy of IFN-based versus IFN-free regimens for treatment of HCV genotype 1 
infections
HCV genotype 1 infection is the most prevalent genotype among all genotypes [8]. So, the 
drug trials are also largely assessed on this genotype. Previously, the combination of PegIFN 
alfa with ribavirin was widely used. However, after the introduction of directly acting anti-
viral (DAA) agents, either they were used in combination with PegIFN and ribavirin or they 
were used in combination with themselves as two DAAs or four DAAs regimen. The efficacy 
and tolerability were superior to the previously standard regimen (PegIFN alfa and ribavirin) 
and also duration was significantly reduced from 24–72 to 12–24 weeks. The IFN-free regi-
mens were better preferred due to higher efficacy rate and fewer adverse effects compared 
to combination of PegIFN regimens. However, we cannot exclude the fact that PegIFN and 
ribavirin remain the ultimate option in setting where no other options are available [4, 12, 14]. 
The different regimens and their efficacy for treatment of genotype 1 infection are given in 
Table 2.
Treatment  
regimens
Naïve (SVR) Treatment-
experienced (SVR)
Partial 
responders
Null responders Relapsers
PegIFN alfa/
ribavirin
SVR 24/48: 42–46%
SVR: 49% in North 
America and 50% 
Western Europe
– – – –
PegIFN/RBV + 
boceprevir
SVR 24/44wks
(NB): 67–68%
(B): 42–53%
SVR32: 59–66%
SVR44: 88%
– – –
PegIFN/RBV + 
telaprevir
(in previously 
untreated patients)
T12PR: 75%
T8PR: 69%
T12PR24: 61%
T12PR48: 67%
PWID: 71%
Non-PWID: 72%
– 68% 46% –
PegIFN alfa/RBV + 
simeprevir
SVR12:
80% (overall)
(1a–71%
1b–90% )
NCN: 81%
– SVR 24: 
48–86% 
(1a-56%
1b-88%)
C: 82%
NCN: 70%
SVR 24: 38–59% 
(1a-42% 1b-58%)
C: 31%
NCN: 44%
SVR24:
77–89%
C: 73%
NCN: 79.2%
PegIFN alfa/RBV + 
sofosbuvir
SVR12: 89% (overall)
(1a-92%, 1b-82%)
C: 80%
SVR4: 85% (overall)
NC: 90%
C: 70%
SVR 12:
NC: 77%
C: 62%
– – –
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2.1.1. Pegylated interferon alpha and ribavirin
The combination of pegylated interferon alpha and ribavirin was a standard regimen previously 
in treatment of hepatitis C genotype 1 infection. The main drawback with this regimen was 
longer duration of treatment course, that is, 24–72 weeks. With this regimen, HCV genotype 
1 infected patient had SVR rates of approximately 40% in North America and 50% in Western 
Europe [18]. The SVR rate was comparatively lower in genotype 1 than other genotypes. The 
Treatment  
regimens
Naïve (SVR) Treatment-
experienced (SVR)
Partial 
responders
Null responders Relapsers
Sofosbuvir+ 
simeprevir
SVR12:
91% (+RBV)
95% (−RBV)
SVR12: 88% (NC)
75% (C)
SVR12: 87% (NC)
76% (C)
– Non-responders 
91%
–
Sofosbuvir + 
ledipasvir
SVR8 (NC):
94% (−RBV)
93% (+RBV)
95%(+RBV* 12wks)
SVR12:
99% (−RBV)
97% (+RBV)
SVR24:
98% (−RBV)
99% (+RBV)
SVR12 (overall):
94% (−RBV)
96% (+RBV)
SVR24:
99% (−RBV)
99% (+RBV)
– – –
Sofosbuvir+ 
daclatasvir
NC: 100% (±RBV)
Cirrhotic:
SVR12: 84.9%
SVR24: 93.4%
– – NC:
100%
(−RBV)
95%
(+RBV)
–
Sofosbuvir + 
velpatasvir
– SVR12 (overall):
98% (1a)
99% (1b)
– – –
Ritonavir-boosted 
paritaprevir, 
ombitasvir, 
dasabuvir ± RBV
SVR12-1a (NC):
95–97% (+RBV)
90% (−RBV)
91% (+HIV)
SVR12-1b (NC):
98–100% (−RBV)
97–100% (+RBV)
SVR12 (C):
92% (1a)
99% (1b)
SVR12 (NC):
96% (1a)
97% (1b)
CC:
SVR12: 92%
SVR24: 96%
NC: 100% NC: 95% NC: 95%
PegIFN alfa-pegylated interferon-alfa; RBV-ribavirin; T12PR-telaprevir, pegylated interferon-alfa and ribavirin for 
12 weeks; T12PR24-telaprevir, pegylated interferon-alfa and ribavirin for 12 weeks, then pegylated interferon-alfa 
and ribavirin for remaining 12 weeks (total 24 weeks); T12PR48-telaprevir, pegylated interferon-alfa and ribavirin for 
12 weeks then pegylated interferon alfa and ribavirin for remaining 36 weeks (total 48 weeks); NCN, non-cirrhotic naïve; 
C, cirrhotic; CC, compensated cirrhosis; NB, non-black patients; B, Black patients; PWID, people who inject drugs; SVR 
4/8/12/24/48, sustained virological response at 4 weeks, 8 weeks, 12 weeks, 24 weeks or 48 weeks; (+) RBV, with ribavirin; 
(−)RBV, without ribavirin; (±) RBV, with or without ribavirin
Table 2. Efficacy of IFN-based vs. IFN-free regimens for treatment of HCV genotype 1 infections.
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previous studies showed SVR of 42–46% infected with genotype 1, treated for 24 or 48 weeks 
[18, 19]. The HIV co-infected patients had SVR of 40% with this regimen [20]. This regimen 
is contraindicated in patients with uncontrolled depression, psychosis, or epilepsy, pregnant 
women or couples unwilling to comply with adequate contraception, severe concurrent medical 
diseases and co-morbidities including retinal disease, autoimmune thyroid disease, and decom-
pensated liver disease. In patient with hepatitis B co-infection, this regimen is used as monoin-
fected patients, although there is a potential risk of hepatitis B infection reactivation during 
HCV clearance [12].
2.1.2. Boceprevir in combination with pegylated interferon alfa and ribavirin
Boceprevir is a first generation NS3/4A protease inhibitors (PIs) approved by FDA in 2011. 
Introduction of PIs constituted a milestone in treating CHC infection, achieved SVR rates of 
up to 75% in naïve and 29–88% in treatment-experienced patients with GT-1 infection [21, 22]. 
However, low genetic barrier to resistance is the main limitation. Introduction of newer DAAs 
replaced the choice of this regimen. The phase 1 and 2 double blind studies carried out for 
untreated HCV genotype 1 infection in non-black and black populations who were treated for 
24–44 weeks showed SVR of 67–68 and 42–53%, respectively [23]. Another study of 403 patients 
previously treated with PegIFN alfa/RBV regimen, the triple therapy with boceprevir for 32–44 
weeks showed SVR of 59–66%. Among patients with an undetectable HCV RNA level at week 
8, SVR was 86 and 88% after 32 and 44 weeks of triple therapy, respectively [24]. A study done 
in 179 cases who inject drugs (PWID) versus non-PWID with this regimen showed SVR of 71 
and 72%, respectively. Among them, 53% were advanced stage (F3–4) and 44% were on antivi-
ral therapy [25]. The main side effect of this regimen was anaemia 21–46% for which erythro-
poietin has to be used or treatment had to discontinue 1–2% [24].
2.1.3. Telaprevir in combination with pegylated interferon alfa and ribavirin
Telaprevir is a first generation NS3/4A protease inhibitors (PIs) approved by FDA in 2011. 
Telaprevir, a protease inhibitor specific to the HCV non-structural 3/4A serine protease, 
rapidly reduced HCV RNA levels in early studies. A study with this regimen grouped into 
Telaprevir/PegIFN alfa/RBV (TPR) 12 weeks; T12PR24; and T12PR48 showed sustained viro-
logical response of 35, 61 and 67%, respectively [26]. In phase 3 trial with triple therapy in 
previously untreated genotype 1 infected cases showed T12PR and T8PR SVR of 75 and 69%, 
respectively [27]. Previously in non-responders and partial responders, the SVR of 44 and 
70%, respectively, was achieved [28]. A study done in 179 cases who inject drugs (PWID) ver-
sus non-PWID with this regimen showed SVR of 71 and 72%, respectively. Among them, 53% 
were advanced in stage F3–4 and 44% were on antiviral therapy [25]. The main adverse effect 
10–21% with telaprevir was anaemia, gastrointestinal side effect, and skin rash. Rash was the 
most common reason for discontinuation of therapy [26, 27].
2.1.4. Simeprevir in combination with pegylated interferon alfa and ribavirin
Simeprevir (TMC435) is an oral HCV NS3/4A protease inhibitor used in combination with 
PegIFN alfa and ribavirin to treat HCV genotype 1 infected patients. This combination is 
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generally well tolerated with potent antiviral activity and pharmacokinetic profile. In ASPIRE 
phase IIb trial done in previously treated patients with PegIFN and ribavirin, the SVR at 24 
weeks was 38–59% (1a-42 and 1b-58%) in prior null responders, 48–86% (1a-56 and 1b-88%) in 
prior partial responders, and 77–89% (no difference) in prior relapsed cases. There were same 
SVR rates in patient with or without Q80k polymorphism at baseline 60.9%. In patients with 
cirrhosis (METAVIR score F4), combination therapy with 150 mg of simeprevir had SVR rate 
at 24 weeks was 73% in prior relapsers, 82% in prior partial responders, and 31% in prior null 
responders [29]. Another phase 3 trial on partials and null responders showed SVR of 70 and 
44%, respectively [28]. According to QUEST 1 & 2 phase 3 study, overall SVR 12 in previously 
untreated and treated naïve patients was 81 (209/257) and 80% (1a-71 and 1b-90%). On sub-
type analysis, SVR rates on with or without Q80K polymorphism at baseline in 1a were 52–75 
and 80–85%, respectively, and 82% in 1b. The SVR rates were comparatively higher in F0–2 
83–85% than F3–4 66–70% [30, 31]. In patients who relapsed on previous therapy, the SVR 12 
was 79.2%. Among them, 92.7% were enabled to shorten therapy with PR at 24 weeks [32]. 
The cause of treatment failure with this regimen was viral breakthrough in 10.6–13%. The 
main side effects were fatigue, headache, pruritus, and influenza like illness and anaemia. 
Skin rash and photosensitivity were also very common with simeprevir [29–32].
2.1.5. Sofosbuvir in combination with pegylated interferon alfa and ribavirin
Sofosbuvir is a nucleotide analogue HCV NS5B polymerase inhibitor with similar in vitro 
activity against pan-HCV genotypes. This therapy is used for HCV pan-genotype infec-
tions (1–6 genotypes) treatment-naïve patients with or without cirrhosis but no evidence on 
treatment-experienced patients. In the NEUTRINO phase III trial in treatment-naïve patients, 
the overall SVR rate was 89% (259/291), 92% (207/225) for subtype 1a and 82% (54/66) for 
subtype 1b. Cirrhotic patients had a lower SVR rate than non-cirrhotic patients (80 vs. 92%, 
respectively) [33]. According to two large-scale US real-life studies, the overall SVR4 rate 
was 85% (140/164, treatment-naïve—55% and treatment-experienced—45%). SVR4 rate was 
90% (114/127) in non-cirrhotic compared to 70% (26/37) in cirrhotic patients [34]. In TRIO 
real-life study including treatment-naïve (58%) and treatment-experienced (42%), SVR12 was 
81 (112/138) and 81% (25/31) in non-cirrhotic and cirrhotic treatment-naïve patients, respec-
tively, and 77% (30/39) in non-cirrhotic treatment-experienced and 62% (53/85) in cirrhotic 
treatment-experienced patients [21].
2.1.6. Sofosbuvir and simeprevir plus ribavirin
In COSMOS study, the combination of sofosbuvir and simeprevir with or without ribavirin for 
12 or 24 weeks was assessed in naïve or null responders infected with genotype 1 patient with-
out severe fibrosis. SVR12 was achieved in 91% (98/108) with ribavirin vs. 95% (56/59) of those 
who did not. SVR rates were similar by treatment status, treatment-naïve 95% (38/40) vs. pre-
vious non-responders 91% (116/127) or treatment duration 94% (77/82) after 12 weeks vs. 91% 
(77/85) after 24 weeks. Neither ribavirin nor treatment duration had clear effect on sustained 
virological response in HCV-infected patients with Gln80Lys polymorphism at baseline [22]. 
In TRIO real-life study, SVR12 achieved in 88% (68/88) of non-cirrhotic treatment-naïve and 
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75% (41/55) of cirrhotic treatment-naïve patients, whereas 87 (64/74) and 76% (53/70) in non-
cirrhotic and cirrhotic treatment-experienced patients, respectively [21].
2.1.7. Sofosbuvir and ledipasvir plus ribavirin
Three phase III trials ION-1-3 have assessed the combination of sofosbuvir with ledipasvir, an 
NS5A inhibitor with or without ribavirin in genotype 1 infected populations. In naïve patients, 
including 16% compensated cirrhotic populations in ION-1 showed SVR12 in 99 (211/214) 
and 97% (211/217) patients after 12 weeks combination therapy without or with RBV, respec-
tively. The SVR12 rate was 98% (212/217) in without RBV and 99% (215/217) in with RBV after 
24 weeks [35]. In ION-3, non-cirrhotic treatment-naïve patients, SVR12 was 94% (202/215) with-
out RBV for 8 weeks, 93% (201/216) with RBV for 8 weeks, and 95% (205/216) without RBV for 
12 weeks. However, relapse rates were higher in 8 weeks compared to 12 weeks therapy [36]. In 
ION-2, in treatment-experienced patients including 20% cirrhotic patients, overall SVR12 rates 
were 94 (102/109) and 96% (107/111) without or with RBV, respectively. The SVR rates were 99 
(108/109) and 99% (110/111) without or with RBV after 24 weeks, respectively [37]. The differ-
ent phase III studies were not powered to compare responses to regimens with or without RBV 
or to 12 weeks or 24 weeks of treatment [38].
2.1.8. Sofosbuvir and daclatasvir
Daclatasvir is a potent, pan-genotypic NS5A inhibitor with antiviral activity against HCV 
genotypes 1–6 in vitro [39], combined with sofosbuvir for treatment of hepatitis C. In phase IIb 
trial in patient without cirrhosis, the 24 weeks of therapy achieved SVR rates of 100% (14/14 and 
15/15) without or with ribavirin, respectively, in treatment-naïve patients, and 100% (21/21) 
without ribavirin and 95% (19/21) with ribavirin non-responders to combination therapy of 
PegIFN alfa, ribavirin, and either telaprevir or boceprevir. Whereas SVR rates were achieved 
in 98% (40/41) of treatment-naïve without ribavirin after 12 weeks of therapy [40]. In phase II 
clinical trial, the efficacy of sofosbuvir plus daclatasvir with or without ribavirin for 12 or 24 
weeks has been evaluated in large real-life cohort including genotype 1 cirrhotic patients. The 
SVR12 rates were 84.9% after weeks and 93.4% after 24 weeks of treatment. However, major-
ity of analyses performed on data available after 4 weeks of follow up showed SVR4 rates of 
85.2% with 12 weeks and 95.1% with 24 weeks of treatment without RBV, whereas 100% with 
12 weeks and 98.7% with 24 weeks treatment with RBV [41]. In cirrhosis, the addition of RBV 
improved SVR, SVR4 of 76.5% with 12 weeks vs. 94% with 24 weeks without RBV treatment, 
which rose to 100 and 98.3%, respectively, with RBV. In non-cirrhotic patients, SVR4 achieved 
in all regardless of use of RBV or treatment duration. Without RBV, SVR4 in treatment-naïve 
after 12 or 24 weeks was 87.1 vs. 88.7%; however, rates increased to 100% (for both duration) 
with addition of RBV. In treatment-experienced patients, SVR4 without or with RBV after 12 
weeks was 82.6 vs. 100%, and after 24 weeks 96.7 vs. 98.5% [41].
2.1.9. Sofosbuvir and velpatasvir
Velpatasvir is a new pangenotypic HCV NS5A inhibitor with antiviral activity against HCV 
replicons in genotype 1–6 infections. The combination of sofosbuvir and velpatasvir for 
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12 weeks has been assessed in ASTRAL phase 3 trial in previously treatment-experienced 
patients (PegIFN/RBV with PIs) including cirrhosis, relapsed cases, patients who had detect-
able HCV RNA after PegIFN and ribavirin treatment. The overall sustained virological 
response rate was 98% in subtype 1a and 99% in subtype 1b infected patients [42]. In phase 
II trial in treatment-experienced patients including 50% cirrhosis and treatment failure, the 
combination of sofosbuvir and velpatasvir with or without ribavirin was assessed. The SVR 
showed 100% in without ribavirin and 96% in with ribavirin treatment patients [43]. The over-
all relapse rate was very low, and this regimen was well tolerated in treatment-experienced 
patient including cirrhosis [42, 43].
2.1.10. Ritonavir boosted paritaprevir, ombitasvir, and dasabuvir
In seven phase III trials, in non-cirrhotic treatment-naïve patients, SAPPHIRE-I trial with 
combination therapy with RBV for 12 weeks showed SVR of 95% (307/322) in subtype 1a and 
98% (148/151) in subtype 1b infected patients [44]. In PEARL-IV trial, the combination therapy 
without or with RBV showed SVR of 90 (185/205) vs. 97% (197/100) in subtype 1a treatment-
naïve patients, respectively [45]. In PEARL-III trial in non-cirrhotic treatment-naïve of sub-
type 1b patients, SVR12 rates were 99% (207/209) without RBV vs. 99% (209/210) with RBV 
[45]. TURQUOISE-I study in non-cirrhotic treatment-naïve patients co-infected with HIV-1 
(stable on antiviral treatment – atazanavir or raltegravir), SVR12 rates were 93% (29/31) after 
12 weeks vs. 91% (29/32) after 24 weeks of treatment. The SVR12 rates based on subtypes 1a 
and 1b were 91 (51/56) and 100% (7/7), respectively [46]. In SAPPHIRE-II trial, non-cirrhotic 
treatment-experienced patients (PegIFN-alfa and RBV failures) were treated with this regi-
men in combination with RBC for 12 weeks. The SVR12 rates were 96% (166/173) in subtype 
1a vs. 97% (119/123) in subtype 1b. The overall SVR12 rates were 95% (82/86) in prior relaps-
ers, 100% (65/65) in partial responders, and 95% (139/146) in null responders [47]. In PEARL-II 
trial, SVR12 achieved in 100% (91/91) without RBV vs. 97% (85/88) with RBV in subtype 1b 
infected patients [48]. In compensated cirrhotic treatment-naïve and treatment-experienced 
patients, the SVR rates were 92% (191/208) after 12 weeks vs. 96% (165/172) after 24 weeks of 
treatment with RBV in TURQUISE-II trial. The SVR12 rates were 92% (239/261) in subtype 1a 
vs. 99% (118/119) in subtype 1b infected patients [49].
2.2. Efficacy of IFN-based versus IFN-free regimens for treatment of HCV genotype 2 
infections
HCV genotype 2 is the third most prevalent genotype worldwide [8]. Although PegIFN alfa 
with ribavirin used previously, IFN-free combination of sofosbuvir with ribavirin is the best 
first line treatment option in genotype 2 infection [12]. Other regimens, IFN-based or IFN-free 
could be an option in cases who fail with this regimen (Table 3). The combination of PegIFN 
alfa and ribavirin remains acceptable when all other options are not available [12, 14].
2.2.1. Pegylated interferon alfa and ribavirin
The initial treatment of HCV genotype 2 began with PegIFN alfa alone or combination of 
PegIFN alfa and ribavirin. Although sustained virological response rate was lower than recent 
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newer regimens, this regimen remains acceptable for treatment of genotype 2 where other 
options are not available [12]. In randomised study, the sustained virological response rates 
were 62% (232/372) in 16 weeks vs. 75% (268/356) in 24 weeks treatment course. The chances 
of relapse rates were higher among 16 weeks than 24 weeks [50]. In phase IV single arm study, 
24 weeks therapy with this regimen in previously untreated naïve patients showed end of 
treatment (EOT) and SVR of 100 and 93%, respectively [51]. In phase III multicenter study in 
prior relapsers who were retreated for 24–48 weeks showed a sustained virological response 
rates of 53–81% in 48 weeks retreated patients vs. 75% in 24 weeks retreated patients [52].
2.2.2. Pegylated interferon alfa and ribavirin plus sofosbuvir
In LONESTAR-2 phase IIb study, in treatment-experienced patients infected with HCV 
genotype 2 patients including 14 with cirrhosis received therapy for 12 weeks, the sustained 
virological response rates were 96% [53]. Another study showed that the relapsed cases of 
sofosbuvir and ribavirin regimen treated for 12 weeks were retreated with this regimen for 
12 weeks, achieved SVR [54]. In phase II study in previously untreated naïve patients, the sus-
tained virological responses in 12 or 24 weeks treatment were 92% (23/25) [55]. The main side 
effects with this regimen were fatigue, headache, nausea, pain, and insomnia [55].
Treatment 
regimens
Naïve Treatment-experienced Partial responders Null responders Relapsers
PegIFN alfa/
ribavirin
SVR 24:
62% (16 weeks)
75% (24 weeks)
24 weeks therapy: 
SVR: 93%
EOT: 100%
SVR24:75%
SVR48: 53–81% (48 
weeks)
– – –
PegIFN/RBV + 
sofosbuvir
SVR12: 92% SVR12: 96% (overall) – – –
Sofosbuvir + 
ribavirin
SVR12:
93–100% (overall)
93–97%(NC)
83–100%(C)
SVR12:
82% (NC)
60% (C)
SVR16:
89% (NC)
78% (C)
SVR12:
91% (NC)
88% (C)
SVR12:
94% (overall)
- - -
Sofosbuvir + 
daclatasvir
SVR12:
92%
– – – –
Sofosbuvir + 
velpatasvir
– SVR12:
99% (overall)
– – –
PegIFN, pegylated interferon-alfa; RBV, ribavirin; EOT, end of treatment; SVR-12/16/24, sustained virological response 
at 12 weeks, 16 weeks and 24 weeks; NC, non-cirrhotic; C, cirrhotic.
Table 3. Efficacy of IFN-based vs. IFN-free regimens for treatment of HCV genotype 2 infections.
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2.2.3. Sofosbuvir and ribavirin
This IFN-free combination therapy is the best first-line treatment option in HCV genotype 
2 infected patients [12]. In FISSION trial in treatment-naïve patients who were treated for 
12 weeks, the SVR was 95% (69/73). The virological response rate was higher in non-cirrhotic 
patients, 97 vs. 83% in cirrhotic patients [33]. In POSITRON trial, who were intolerant or ineli-
gible to IFN, treated for 12 weeks, SVR was 93% (101/109) [56]. The 12 vs. 16 weeks therapy 
was in FUSION trial showed SVR of 82 (32/39) vs. 89% (31/35) in non-cirrhotic and 60 (6/10) 
vs. 78% (7/9) in cirrhotic cases, respectively. The longer than 12 weeks therapy was beneficial 
in cirrhotic population [56]. In VALENCE trial, the treatment was given for 12 weeks in treat-
ment-naïve and treatment-experienced patients with or without cirrhosis. In treatment-naïve 
patients, the SVR rates were 97% (29/30) in without cirrhosis and 100% (2/2) in with cirrhosis. 
In treatment-experienced patients, SVR rates were 91 (30/33) vs. 88% (7/8) in without cirrhosis 
and with cirrhosis, respectively [57]. This combination therapy was well tolerated, and no 
virological breakthroughs were observed in treatment adherent patients [12].
2.2.4. Sofosbuvir and daclatasvir
Daclatasvir, NS5A replication complex inhibitor, is active against HCV genotype 2 in vitro. 
The combination of sofosbuvir with daclatasvir therapy was observed in phase II trial showed 
sustained virological response of 92% (24/26) after 12 weeks of therapy and overall 93% after 
24 weeks of therapy [40]. Based on data with other, 12 weeks is probably sufficient to treat 
more difficult-to-cure HCV genotypes. This regimen should be kept reserved for patients who 
failed with other options in HCV genotype 2 infections [12, 40].
2.2.5. Sofosbuvir and velpatasvir
In 2 phase III trial (open label studies), the combination of sofosbuvir (400 mg) and velpatasvir 
(100 mg) was assessed in patients infected with HCV genotype 2 who previously received 
treatment and who did not received previous treatment including compensated cirrhosis. 
The sustained virological response was achieved in 99% of cases with this regimen [58]. In 
ASTRAL phase III double blind trial in treatment-experienced patients including cirrho-
sis, treatment relapsed, and detectable HCV RNA under PegIFN and ribavirin therapy, the 
SVR12 was 100% in genotype 2 infected patients [42]. From the data available, this regimen 
was well tolerated with higher SVR in treatment of genotype 2 infection. However, these data 
have to be compared with the blind trials or studies.
2.3. Efficacy of IFN-based versus IFN-free regimens for treatment of HCV genotype 3 
infections
There are four treatment options available for treatment of hepatitis C genotype 3 infection 
including one phase III trial drug (Table 4). The IFN-based combination therapy-PegIFN alfa 
and ribavirin regimen remains acceptable only in settings where none other options are avail-
able [12]. The triple combination of PegIFN alfa, ribavirin and sofosbuvir appears to be valu-
able even in, who failed on sofosbuvir and ribavirin combinations. However, it has to be done 
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in larger population infected with HCV genotype 3 patients [54]. The IFN-free combination 
therapy—sofosbuvir and ribavirin—appears to be suboptimal particularly in cirrhotic HCV 
genotype 3 infected patients, although it is the best first line treatment option for genotype 2 
infection [12]. Sofosbuvir and daclatasvir with or without ribavirin are a new attractive option 
for patients infected with genotype 3. Ledipasvir is considerably less potent against genotype 
3 in vitro than daclatasvir. In clinical trials, the combination of ledipasvir with sofosbuvir or 
other agents is not recommended in patients infected with HCV genotype 3 [12, 14].
2.3.1. Pegylated interferon alfa and ribavirin
This combination therapy remained acceptable for treatment of genotype 3 infections until 
the development of other regimens with higher sustained virological response and also in 
setting where other options are not available [12]. In this regimen, the treatment is given for 
24 weeks in genotype 3 infected patients. In phase 4 single arm study in 182 HCV genotype 3 
Treatment 
regimens
Naïve Treatment-experienced Partial 
responders
Null 
responders
Relapsers
PegIFN alfa/
ribavirin
24 weeks:
SVR-79%
EOT-93%
– – – –
PegIFN/RBV + 
sofosbuvir
– SVR12: 83% (+C) – – SVR12: 91%
Sofosbuvir and 
ribavirin
SVR12:
56–61% (overall)
61% (NC)
34% (C)
SVR12 vs. SVR16:
30 vs. 62% (NC)
19 vs. 61% (C)
SVR24:
94%(NC)
92%(C)
SVR24:
80% (overall)
87% (NC)
60% (C)
– – SVR24:
63%
Sofosbuvir and 
daclatasvir
SVR24:
89% (NC)
SVR12 (−RBV):
97% (NC)
58% (C)
SVR12 (−RBV):
94% (NC)
69% (C)
– – –
Sofosbuvir and 
velpatasvir
SVR12 (overall):
95%
SVR12 (NC):
100% (±RBV)
SVR12 (C):
88% (−RBV)
96% (+RBV)
– – –
PegIFN, pegylated interferon-alfa; RBV, ribavirin; SVR 12/24, sustained virological response at 12 weeks and 24 weeks; 
EOT, end of treatment; NC, non-cirrhotic; C, cirrhotic.
Table 4. Efficacy of IFN-based vs. IFN-free regimens for treatment of HCV genotype 3 infections.
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infected population and treatment was given with this regimen for 24 weeks; the overall sus-
tained virological response rate was observed and also at end of treatment (EOT). It showed 
EOT and SVR were of 93 and 79%, respectively [51]. Baseline viremia, treatment duration 
>16 weeks, and steatosis were independent predictors of SVR. The relapsed rate were higher 
among male and older age >55 years [51].
2.3.2. Pegylated interferon alfa and ribavirin plus sofosbuvir
In LONESTAR-2 phase IIb trial, in treatment-experienced patients infected with HCV gen-
otype 3, the sustained virological response rate was 83% (20/24) including (10/12) patients 
with cirrhosis [53]. However, pangenotypic activity of sofosbuvir together with higher SVR in 
other genotypes 89% (overall in genotype 1, 4 or 6) indicates this regimen can be safely used 
in patients with genotype 3 infections [53]. In phase 2 trial, in non-cirrhotic treatment-naïve 
patients were treated for 12 weeks, the sustained virological response was achieved in 92% 
(23/25) cases [55]. In another study, patients who relapsed after treatment with sofosbuvir and 
ribavirin regimens were retreated with this triple combination therapy for 12 weeks, and the 
SVR was achieved in 91% (20/22) cases [54].
2.3.3. Sofosbuvir and ribavirin
The combination of sofosbuvir with daily fixed dose ribavirin is used for treatment of geno-
type 3 infection for 24 weeks. In FISSION trial, in treatment-naïve patients who were treated for 
12 weeks, the SVR rate was 56% (102/183). The non-cirrhotic patients had better SVR of 61 vs. 34% 
in cirrhotic patients [33]. In POSITRON trial, patients were also treated for 12 weeks with this 
regimen who were ineligible or intolerant to interferon. The SVR rate was 61% (60/98) of cases. 
In FUSION trial, the 12 vs. 16 weeks treatment was compared. The SVR rate was significantly 
higher, 62% in non-cirrhotic and 61% in cirrhotic patients with 16 weeks treatment compared to 
30% in non-cirrhotic and 19% in cirrhotic patient with 12 weeks treatment [56]. In VALENCE trial, 
treatment was given for 24 weeks in both treatment-naïve and treatment-experienced without or 
with cirrhosis. In treatment- naïve, the SVR24 was 94% (86/92) in non-cirrhotic and 92% (12/13) in 
cirrhotic patients. Whereas, in treatment-experienced, SVR 24 was 87% (87/100) in non-cirrhotic 
and 60% (27/45) in cirrhotic patients [57]. So based on these studies, 24 weeks treatment is appro-
priate for the HCV genotype 3 infected patients. Another study, in relapsed cases with sofosbuvir 
and ribavirin, patients were retreated for 24 weeks, achieved SVR only of 63% (24/38) of cases, 
indicating the regimen is suboptimal in such patients with HCV genotype 3 infection [54].
2.3.4. Sofosbuvir and daclatasvir
In treatment of HCV genotype 3 infected patients, this regimen is given for 12 weeks in 
non-cirrhotic patients and 24 weeks with daily weight-based ribavirin for 24 weeks in cir-
rhotic patients. In phase IIb trial, after 24 weeks of combination therapy, SVR rate was 89% 
(16/18) in treatment-naïve without cirrhosis [40]. In ALLY-3 phase III trial, after 12 weeks 
of combination therapy without ribavirin, SVR12 was 97% (73/75) in non-cirrhotic and 58% 
(11/19) in cirrhotic treatment-naïve patients, whereas SVR12 was 94 (32/34) and 69% (9/13) 
in treatment-experienced patients without or with cirrhosis, respectively [59]. This regimen 
was well tolerated with rare adverse events, and none of them discontinued treatment [12].
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2.3.5. Sofosbuvir and velpatasvir
In phase II trial, the combination of sofosbuvir (400 mg) and velpatasvir (100 mg) with 
or without daily fixed dose ribavirin for 12 weeks was assessed in treatment-experienced 
patients with or without cirrhosis infected with HCV genotype 3. The sustained virological 
response was achieved 100% with or without ribavirin in non-cirrhotic patients. However, 
SVR of 88% without ribavirin and 96% with ribavirin was achieved in compensated cir-
rhotic patients [43]. In another 2 phase III trial (open label studies), in patients infected with 
genotype 3 who have previously received treatment and who did not receive treatment 
including compensated cirrhosis, 12 weeks of this regimen without ribavirin achieved SVR 
of 95% [58]. Based on these studies, this regimen was well tolerated in treatment of HCV 
genotype 3 infections.
2.4. Efficacy of IFN-based versus IFN-free regimens for treatment of HCV genotype 4 
infections
There are seven treatment options available for treatment of hepatitis C genotype 4 infections, 
including two IFN-based regimens and four IFN-free regimens (Table 5). The combination of 
PegIFN alfa and ribavirin remains acceptable only in that case where other options are not 
available [12].
Treatment regimens Naïve Treatment-experienced Partial 
responders
Null 
responders
Relapsers
PegIFN alfa/
ribavirin
SVR24: 29%
SVR36: 66%
SVR48: 69%
PegIFN/RBV + 
simeprevir
SVR24: 93% – SVR48: 60% SVR48: 40% SVR24: 86%
PegIFN/RBV + 
sofosbuvir
SVR 12: 96% – – – –
Sofosbuvir + 
simeprevir
SVR12:
>98% (F1–2)
80–97.7% (F3–4)
SVR12:
98–100% (F1–2)
88–94.7% (F3–4)
– – –
Sofosbuvir+ 
ledipasvir
SVR12: 95%
(−RBV)
– – – –
Sofosbuvir+ 
daclatasvir
– – – - -
Sofosbuvir and 
velpatasvir
– SVR12 (overall): 100% (+C/R) – – –
Ritonavir boosted 
paritaprevir, 
ombitasvir
SVR12:
100% (+RBV)
90.9% (−RBV)
SVR12 (+RBV): 100% – – –
PegIFN, pegylated interferon-alfa; RBV, ribavirin; SVR 12/24/36/48, sustained virological response at 12 weeks, 24 weeks, 
36 weeks and 48 weeks; (+)C/R, with cirrhosis and relapse; (−)RBV, with ribavirin; (+) RBV, with ribavirin.
Table 5. Efficacy of IFN-based vs. IFN-free regimens for treatment of HCV genotype 4 infections.
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2.4.1. Pegylated interferon alfa and ribavirin
The combination of PegIFN alfa and ribavirin is still the option for treatment of HCV genotype 4 
when other options are not available [12]. In prospective randomise controlled trial, the combina-
tion of PegIFN alfa and ribavirin was used for 24–48 weeks. The sustained virological response 
rates were 29 vs. 66 vs. 69% in 24 vs. 36 vs. 48 weeks of treatment, respectively [60].
2.4.2. Pegylated interferon alfa and ribavirin plus simeprevir
Simeprevir is active against HCV genotype 4 in vitro. So, this combination therapy can be used 
in genotype 4 infection. However, the duration of therapy is 24 weeks (SPR 12 + PR 12 weeks) 
in treatment-naïve or prior relapsers including cirrhosis and 48 weeks (SPR12 + PR 36 weeks) in 
prior partial or null responders including cirrhosis. In phase III study, SVR12 was achieved in 
83% (29/35) in treatment-naïve patients, 86% (19/22) in prior relapsers, 60% (6/10) in prior par-
tial responders, and 40% (16/40) in prior null responders. This regimen was effective in treat-
ment-naïve and prior relapsers, however, suboptimal in prior partial and null responders [61].
2.4.3. Pegylated interferon alfa and ribavirin plus sofosbuvir
In NEUTRINO phase III in treatment-naïve patients, this combination therapy for 12 weeks 
was evaluated. The SVR rate was 96% (27/28) in HCV genotype 4 infected patients [33]. Those 
who failed in this combination therapy did not select HCV variants resistant to sofosbuvir. No 
data were available in treatment-experienced or HIV-coinfected patients [12].
2.4.4. Sofosbuvir and ledipasvir
Sofosbuvir in combination with ledipasvir is used in treatment-naïve and treatment-experienced 
patients with or without cirrhosis for 12 weeks. Addition of ribavirin to this therapy has ben-
eficial effect in cirrhotic individuals. In SYNERGY trial, efficacy and safety of combination of 
sofosbuvir and ledipasvir without ribavirin are assessed in patient with genotype 4 infection. 
The sustained virological response was achieved in 95% (20/21) of cases [62]. The shorter 8 weeks 
treatment duration as in patients infected with genotype 1 infections is not clear due to lack of 
data in genotype 4 infected cases [12].
2.4.5. Sofosbuvir and simeprevir
The unavailability of data on treatment of HCV genotype 4 infection had questioned the 
use of this IFN-free regimen (sofosbuvir plus simeprevir) as an option previously, however, 
according to a very recently published two studies, sofosbuvir (SOF) plus simeprevir (SIM) 
regimen with or without ribavirin, can be a good option in treating HCV genotype 4 infected 
cases [12, 63, 64]. A retrospective multicentre observational study in 53 patients (naïve or 
experienced patients) including advanced liver fibrosis or liver cirrhosis treated with SOF and 
SIM with or without ribavirin showed a SVR12 of 92% (49/53). In this study, treatment failures 
were observed in those who didn’t receive ribavirin and interferon non-responders except one 
naïve patient [63]. Another multicentre observational study in 583 patients infected with HCV 
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genotype 4 showed the overall SVR rates of 95.7% (558/583) with SOF/SIM regimen. Based 
on fibrosis stages in naïve patients, mild fibrosis score had better SVR12 of 98.9% (94/95) in 
F1 and 98.1% (105/107) in F2 stage than severe fibrosis score with SVR12 of 97.7% (86/88) in 
F3 and 80.8% (42/52) in F4 stage. While in treatment-experienced patients with severe fibrosis 
score, SVR12 was 94.7% (72/76) in F3 and 88.9% (40/45) in F4 stage. In addition, patients who 
were previously treated with interferon had SVR of 100% (45/45) in F1 and 98.7% (74/75) in 
F2 mild fibrosis score [64]. Therefore, this regimen can be efficacious and well tolerated in 
treatment-naïve and experienced patients including severe fibrosis score or liver cirrhosis. 
Furthermore, the addition of ribavirin could be considered especially in treatment-experi-
enced and advanced cirrhosis patients as recommended by recent AASL and EASL guidelines 
[12, 14, 63, 64].
2.4.6. Sofosbuvir and daclatasvir
Daclatasvir has its antiviral activity against genotype 4 in vitro. The combination of sofosbuvir 
and daclatasvir with or without ribavirin is effective in treating patients infected with HCV gen-
otype 4. However, there is no data available with this combination in treatment of this genotype. 
Nevertheless, both sofosbuvir and daclatasvir have antiviral effectiveness against genotype 4 in 
vitro. So, the results in patients infected with genotype 1 can be extrapolated [12].
2.4.7. Sofosbuvir and velpatasvir
Velpatasvir and sofosbuvir have a pangenotypic action for treatment of HCV genotype 1–6 
infections. The combination of sofosbuvir and velpatasvir assessed in ASTRAL phase 3 trial 
in previously treatment-experienced patients (PegIFN/RBV with PIs) including cirrhosis, 
relapsed cases, patients who had detectable HCV RNA after PegIFN and ribavirin treatment. 
The overall sustained virological response rate was 100% in genotype 4 infected patients. The 
overall relapse rate was very low, and this regimen was well tolerated in treatment-experi-
enced patient including cirrhosis [42].
2.4.8. Ritonavir-boosted paritaprevir and ombitasvir
A fixed dose ritonavir, paritaprevir, and ombitasvir with or without ribavirin treatment for 
12–24 weeks were assessed in treatment-naïve and treatment-experienced patients with or 
without compensated cirrhosis infected with HCV genotype 4. According to PEARL-I trial in 
non-cirrhotic chronic HCV genotype 4 infected patients, sustained virological response rates 
were 100% in treatment-naïve (42/42) and treatment-experienced patients (49/49) with ribavi-
rin regimen, whereas 90.9% (40/44) in treatment-naïve patients without ribavirin regimen for 
12 weeks [65]. In AGATE-I trial with a fixed dose ritonavir, paritaprevir, and ombitasvir plus 
ribavirin in chronic HCV genotype 4 infected treatment-naïve and treatment-experienced 
patients including compensated cirrhosis, post-treatment sustained virological response rates 
were 97% (57/59) in 12 weeks and 98% (60/61) in 16 weeks group [66]. In addition, AGATE-II 
trial in Egyptian patients, SVR12 was 94% (94/100) in patients without cirrhosis, whereas 
SVR12 of 97% (30/31) and SVR24 of 93% (27/29) in patients with cirrhosis [67]. Extension 
of this treatment regimen beyond 12 weeks (16 and 24 weeks) for HCV genotype 4 infected 
Comparative Study of IFN-Based Versus IFN-Free Regimens and Their Efficacy in Treatment of Chronic Hepatitis C...
http://dx.doi.org/10.5772/67214
65
patients with compensated cirrhosis seemed to have no additional benefits [66, 67]. This regi-
men was generally well tolerated by chronic HCV genotype 4 infected patients with or with-
out compensated cirrhosis in clinical trials, so this regimen is a valuable option, although 
having postmarking reports of hepatic decompensation and hepatic failure mainly in patients 
with advanced cirrhosis [68].
2.5. Efficacy of IFN-based versus IFN-free regimens for treatment of HCV genotypes 5 or 6 
infections
HCV genotype 5 is the least prevalent worldwide and then genotype 6 infection [8]. The 
treatment options for these genotypes are one IFN-based triple combination of PegIFN alfa, 
ribavirin, and sofosbuvir; and three IFN-free combination therapy: sofosbuvir and ledipasvir, 
sofosbuvir and daclatasvir, and sofosbuvir and velpatasvir (Table 6). IFN-based combination 
of PegIFN-alfa and ribavirin remains acceptable in setting where other treatment options are 
not available [12].
2.5.1. Pegylated interferon alfa and ribavirin plus sofosbuvir
In NEUTRINO phase III trial, this combination therapy has been evaluated in treatment-
naïve patients. There were total seven patients (one infected genotype 5 and six infected with 
genotype 6), all patients achieved sustained virological response [33]. However, no data have 
been presented with this regimen in treatment-experienced patients. So, it is not clear whether 
longer duration of treatment is needed [12].
2.5.2. Sofosbuvir and ledipasvir
Ledipasvir is active against both genotype 5 or 6 in vitro. The combination of sofosbuvir 
and ledipasvir is used in treatment of these genotypes. Those patients without cirrhosis, 
Treatment 
Regimens
Naïve Treatment-experienced Partial responders Null 
responders
Relapsers
PegIFN/RBV + 
sofosbuvir
SVR12: 90% – – – –
Sofosbuvir and 
ledipasvir
SVR (GT-5): 95%
SVR12 (TN+TE): 96% 
(overall)
SVR (GT-5): 95% – – –
Sofosbuvir and 
daclatasvir
– – – – –
Sofosbuvir and 
velpatasvir
SVR12 (overall): 96% SVR12 (overall):
97% (GT-5)
100% (GT-6)
– – –
PegIFN, pegylated interferon alfa; RBV, ribavirin; GT-5, genotype 5; GT-6, genotype 6; SVR12, sustained virological 
response at 12 weeks; TN+TE, treatment-naïve and treatment-experienced.
Table 6. Efficacy of IFN-based vs. IFN-free regimens for treatment of HCV genotype 5 or 6 infections.
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including treatment-naïve and treatment-experienced should be treated for 12 weeks with-
out ribavirin. Addition of ribavirin is recommended in cirrhotic cases. However, 24 weeks 
combination of sofosbuvir and ledipasvir is recommended, when ribavirin is contraindicated 
or with poor tolerance [12]. In multicentre open label phase II trial, in treatment-naïve and 
treatment-experienced patients infected with genotype 5 including cirrhosis, the overall SVR 
was 95% (39/42). The SVR was 95% (20/21) in treatment-naïve and 95% (19/20) in treatment-
experienced patients. However, SVR was 97% (31/32) in non-cirrhotic vs. 89% (8/9) in cirrhotic 
patients [69]. In phase 2 clinical trial, in treatment-naïve and treatment-experienced patients 
infected with HCV genotype 6, the 12 weeks treatment with this regimen without ribavirin 
had a sustained virological response of 96% (24/25) [12, 70].
2.5.3. Sofosbuvir and daclatasvir
Daclatasvir and sofosbuvir are active against genotype 5 or 6 in vitro. This regimen is given 
for 12 weeks with or without ribavirin in these genotypes. However, in cirrhotic patients 
with contraindications or intolerance to ribavirin, combination therapy can be extended to 
24 weeks. There were no data available with this regimen for these rare genotypes [12].
2.5.4. Sofosbuvir and velpatasvir
The combination of sofosbuvir (400 mg) and velpatasvir (100 mg) for 12 weeks was assessed in 
ASTRAL phase III trial for treatment of genotypes 5 and 6. In this double blind, placebo con-
trolled trial, patients were previously treatment-experienced (PegIFN and ribavirin or PegIFN, 
ribavirin and protease inhibitors), relapsed cases, and who had persistent detectable HCV RNA 
on PegIFN alfa and ribavirin therapy. The sustained virological response achieved in patients 
infected with genotypes 5 and 6 were 97 and 100%, respectively. This regimen was well tolerated, 
with very low failure rate in treatment of HCV genotype 5 and 6 infections [42]. In another ran-
domised trial, the overall sustained virological response was 95% in treatment-naïve patients [71].
3. Discussion
The development of DAAs was the milestone in the treatment of chronic hepatitis C, and their 
combination therapy became the first option for almost all genotypes. However, the IFN-based 
combination therapies have their own role in treatment of chronic hepatitis C infections when 
DAAs combination regimens are unavailable or fails [12]. In genotype 1 infections, the IFN-
based combination therapy: PegIFN alfa, RBV, and simeprevir, and PegIFN, RBV, and sofosbuvir 
combination had higher overall SVR of 60–90% including relapsers or partial/null responders 
compared to other three regimens. In IFN-free regimens, all the DAAs combination regimens 
(2/4 DAAs ± RBV) have overall SVR of above 90% [12, 14]. The combination of sofosbuvir with 
ledipasvir or daclatasvir velpatasvir or 4DAAs (ritonavir, paritaprevir, ombitasvir, & dasabuvir) 
had superior SVR rates compared to IFN-based regimens [35, 36, 40, 42, 44]. In HCV genotype 2 
infections, though PegIFN alfa with RBV and sofosbuvir has higher SVR >90%, the combination 
of sofosbuvir and ribavirin is the first line regimen for its treatment [33]. Although combination 
of sofosbuvir with daclatasvir or velpatasvir has SVR > 90%, they are reserved for treatment 
Comparative Study of IFN-Based Versus IFN-Free Regimens and Their Efficacy in Treatment of Chronic Hepatitis C...
http://dx.doi.org/10.5772/67214
67
failed options with first line drugs [40–43]. In genotype 3 infections, the combination of sofosbu-
vir and ribavirin is suboptimal [54], so IFN-based PegIFN/RBV/SOF regimen or IFN-free com-
bination of SOF and daclatasvir becomes the choice of treatment [40, 54, 59]. The phase 3 trials, 
sofosbuvir and velpatasvir have higher SVR, so it might be the choice of regimen in future [43, 
58]. In genotype 4 infections, IFN-based PegIFN, RBV with simeprevir or sofosbuvir have SVR > 
90% in treatment-naïve cases. However, SVR in partial or null responders is suboptimal [33, 61]. 
The IFN-free two DAAs or three DAAs with or without RBV has overall SVR > 90%, although 
no data available for partial or null responders or relapsers cases [42, 62, 65, 72]. In genotype 5 
or 6 infections, IFN-based PegIFN/RBV/SOF has SVR of 90% in treatment-naïve [33]. However, 
two DAAs combinations have better SVR of > 95% [12, 43, 69, 70]. In this review, it showed that 
IFN-free DAAs regimens have better SVR and well tolerated compared to IFN-based regimen. 
The combination of DAAs with or without ribavirin has almost replaced the IFN-based combina-
tion therapy in present context. Nevertheless, we cannot exclude the fact that the combination of 
PegIFN alfa and ribavirin still leaves us an ultimate option in setting where all other options are 
not available [12, 14].
4. Conclusion
The combination of IFN-free DAAs regimens has superior in their efficacy and tolerability 
compared to IFN-based regimens in case of treatment of chronic hepatitis C in all genotypes. 
However, in genotypes 3, 4, 5 or 6, the IFN-based combination of pegylated interferon alfa, 
ribavirin, and sofosbuvir can be an option in case of treatment failure with DAAs first line 
regimens. Nevertheless, this is not mentioned in the retreatment guidelines, and this is just an 
assumed recommendation that needs to be evaluated in trials.
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